Table 1 Patients’ characteristics in the French multicenter cohort and the training cohort in the study by Zhang et al.
French cohort (N = 601) | Chinese training cohort (N = 1955) | |
|---|---|---|
Age, years, median (IQR) | 58 (47–70) | 40 (30–52) |
Male sex, n (%) | 323 (54) | 1195 (61) |
Spleen size, cm below costal margin, median (IQR) | 0 (0–3) | 3 (0–10) |
White blood cells, ×10E + 9/L, median (IQR) | 64 (30–139) | 122 (47–235) |
Hemoglobin, ×10E + 9/L, median (IQR) | 126 (111–139) | 115 (97–132) |
Platelets, ×10E + 9/L, median (IQR) | 389 (248–600) | 410 (270–635) |
Blood blasts, %, median (IQR) | 0 (0–1.7) | 1 (0–3) |
Blood basophils, %, median (IQR) | 3 (2–5) | 5 (2–8) |
Blood eosinophils, %, median (IQR) | 2 (1–3) | 2 (1–4) |
Sokal risk, n (%) | ||
Low | 206 (34) | 819 (42) |
Intermediate | 278 (46) | 555 (28) |
High | 113 (19) | 394 (20) |
Unknown | 4 (0.7) | 187 (10) |
ELTS risk, n (%) | ||
Low | 321 (53) | 1115 (57) |
Intermediate | 192 (32) | 471 (24) |
High | 83 (14) | 182 (9) |
Unknown | 5 (0.8) | 187 (10) |
Ph+ ACAs, n (%) | 70 (12) | 68 (3) |
High-risk ACAs, n (%) | 32 (5) | 41 (2) |
Comorbidity(ies), n (%) | 180 (30) | 700 (36) |
Initial TKI, n (%) | ||
Imatinib | 397 (66) | 1539 (79) |
2 G TKI | 204 (34) | 416 (21) |
Nilotinib | 143 (24) | 280 (14) |
Bosutinib | 48 (8) | 0 (0) |
Dasatinib | 13 (2) | 72 (4) |
Flumatinib | 0 (0) | 64 (3) |
Follow-up, months, median (IQR) | 47 (19–89) | 56 (30–91) |
